{"schema_version":"secwatch.filing_event.v1","accession":"0001079973-23-001523","form_type":"8-K","ticker":"PDEX","cik":"0000788920","company_name":"PRO DEX INC","filed_at":"2023-11-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:32.008807+00:00","generated_at":"2026-06-09T01:21:32.446362+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Pro-Dex Q1 FY2024 net loss $615k; sales up 8% to $11.9M; includes $2.6M unrealized loss on investment","bullets":["Net loss of $615k ($0.17 diluted) vs net income of $1.2M ($0.33) in prior-year quarter.","Net sales rose 8% to $11.9M; driven by $1.8M increase in handpiece repairs, offset by $0.7M drop in NRE.","Gross margin improved 4 ppts to 31% due to absence of $450k repair costs from prior year.","Unrealized loss on investments of $2.6M (mainly Monogram Orthopaedics warrant) caused the net loss.","CEO cited $1.1M in new Thoracic driver product sales and completion of Franklin facility transition."],"urls":{"canonical":"https://secwatch.observer/filing/0001079973-23-001523","json":"https://secwatch.observer/filing/0001079973-23-001523.json","markdown":"https://secwatch.observer/filing/0001079973-23-001523.md","text":"https://secwatch.observer/filing/0001079973-23-001523.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/788920/000107997323001523/0001079973-23-001523-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/788920/000107997323001523/pdex_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-09T01:21:32.446362+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"65d4636e8fda86e8cd240a876af378cfb1bbfa4d","claim":"PRO DEX INC reported fiscal 2024 first quarter ended September 30, 2023 results: revenue $11.9 million, net income net loss of $615,000, or $0.17 per diluted share.","evidence_excerpt":"the first quarter of fiscal year 2024 with the Securities and Exchange Commission today. Net sales for the three months ended September 30, 2023, increased $851,000, or 8%, to $11.9 million from $11.1 million for the three months ended September 30, 2022. The increase is driven primarily by $1.8 million in increased repairs of the surgical handpiece we sell to our","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/788920/000107997323001523/0001079973-23-001523-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fiscal 2024 first quarter ended September 30, 2023"},{"label":"Revenue","value":"$11.9 million"},{"label":"Net income","value":"net loss of $615,000, or $0.17 per diluted share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}